import type { CompetitorRecord } from './competitor-database';

export const ONCOLOGY_EXTRA_COMPETITORS: CompetitorRecord[] = [

  // ══════════════════════════════════════════════════════════
  // 1. DIFFUSE LARGE B-CELL LYMPHOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Polivy',
    generic_name: 'polatuzumab vedotin-piiq',
    company: 'Roche/Genentech',
    indication: 'Diffuse Large B-Cell Lymphoma',
    indication_specifics: '1L DLBCL in combination with R-CHP; previously R/R DLBCL with BR',
    mechanism: 'Anti-CD79b antibody-drug conjugate (MMAE payload)',
    mechanism_category: 'antibody_drug_conjugate',
    molecular_target: 'CD79b',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'POLARIX: Pola-R-CHP vs R-CHOP, 2-yr PFS 76.7% vs 70.2% (HR 0.73, p=0.02); OS not significant',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First ADC approved in 1L DLBCL', 'PFS advantage over R-CHOP standard of care', 'NCCN Category 1 preferred regimen'],
    weaknesses: ['No OS benefit demonstrated vs R-CHOP', 'Higher peripheral neuropathy rates', 'Premium pricing over generic R-CHOP backbone'],
    source: 'FDA label; POLARIX (NCT03274492); NCCN v5.2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Monjuvi',
    generic_name: 'tafasitamab-cxix',
    company: 'MorphoSys/Incyte',
    indication: 'Diffuse Large B-Cell Lymphoma',
    indication_specifics: '2L+ R/R DLBCL not eligible for autologous SCT, in combination with lenalidomide',
    mechanism: 'Anti-CD19 Fc-enhanced monoclonal antibody',
    mechanism_category: 'monoclonal_antibody',
    molecular_target: 'CD19',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'L-MIND: ORR 57.5%, CR 40.0%, median DOR 43.9 mo; single-arm study in transplant-ineligible patients',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Durable responses with long median DOR', 'Off-the-shelf option (not CAR-T)', 'Fc-enhanced ADCC and ADCP activity'],
    weaknesses: ['Single-arm approval—confirmatory trial InMIND ongoing', 'Requires lenalidomide combination', 'Competition from CAR-T and bispecifics in 2L+'],
    source: 'FDA label; L-MIND (NCT02399085); MorphoSys 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zilovertamab vedotin',
    company: 'VelosBio/Merck',
    indication: 'Diffuse Large B-Cell Lymphoma',
    indication_specifics: 'R/R DLBCL, ROR1-expressing tumors',
    mechanism: 'Anti-ROR1 antibody-drug conjugate (MMAE payload)',
    mechanism_category: 'antibody_drug_conjugate',
    molecular_target: 'ROR1',
    phase: 'Phase 2',
    primary_endpoint: 'ORR',
    key_data: 'Phase 1/2 waveLINE-004: preliminary ORR ~30-40% in heavily pretreated DLBCL; dose optimization ongoing',
    line_of_therapy: '3L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Novel ROR1 target broadly expressed in B-cell malignancies', 'Merck backing provides development resources', 'First-in-class potential'],
    weaknesses: ['Early-stage data with limited sample size', 'ROR1 expression may vary across DLBCL subtypes', 'Crowded late-line DLBCL space with CAR-T and bispecifics'],
    source: 'Merck pipeline; waveLINE-004 (NCT05458297); ASH 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 2. FOLLICULAR LYMPHOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Lunsumio',
    generic_name: 'mosunetuzumab-axgb',
    company: 'Roche/Genentech',
    indication: 'Follicular Lymphoma',
    indication_specifics: 'R/R FL after 2+ prior lines of therapy including anti-CD20 and alkylating agent',
    mechanism: 'CD20xCD3 bispecific T-cell engaging antibody',
    mechanism_category: 'bispecific_antibody',
    molecular_target: 'CD20 / CD3',
    phase: 'Approved',
    primary_endpoint: 'CR rate',
    key_data: 'GO29781: CR rate 60%, ORR 80% in 3L+ FL; fixed-duration treatment (8 cycles responders, 17 cycles non-CR)',
    line_of_therapy: '3L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First bispecific approved in FL', 'High CR rate with fixed-duration dosing', 'Off-the-shelf (no manufacturing wait)'],
    weaknesses: ['CRS in ~44% (grade 3+ ~1%)', 'Single-arm study basis for approval', 'Competition from Columvi and CAR-T in same setting'],
    source: 'FDA label; GO29781 (NCT02500407); Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Columvi',
    generic_name: 'glofitamab-gxbm',
    company: 'Roche/Genentech',
    indication: 'Follicular Lymphoma',
    indication_specifics: 'R/R FL after 2+ prior lines including anti-CD20 antibody',
    mechanism: 'CD20xCD3 bispecific T-cell engaging antibody (2:1 format)',
    mechanism_category: 'bispecific_antibody',
    molecular_target: 'CD20 / CD3',
    phase: 'Approved',
    primary_endpoint: 'CR rate',
    key_data: 'NP30179 FL cohort: CR 71.4%, ORR 81.4%; fixed 12-cycle treatment duration; obinutuzumab pretreatment required',
    line_of_therapy: '3L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Very high CR rate in R/R FL', 'Fixed-duration 12-cycle regimen', 'Roche commercial infrastructure and CD20 franchise'],
    weaknesses: ['Requires obinutuzumab pre-treatment to mitigate CRS', 'CRS in ~63% of patients', 'Competes with own portfolio product Lunsumio'],
    source: 'FDA label; NP30179 (NCT03075696); ASCO 2023',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Odronextamab',
    company: 'Regeneron',
    indication: 'Follicular Lymphoma',
    indication_specifics: 'R/R FL Grade 1-3a after 2+ prior therapies',
    mechanism: 'CD20xCD3 bispecific antibody',
    mechanism_category: 'bispecific_antibody',
    molecular_target: 'CD20 / CD3',
    phase: 'Phase 2',
    primary_endpoint: 'ORR',
    key_data: 'ELM-2 (Phase 2): ORR 80.2%, CR 73.3% in R/R FL; step-up dosing schedule to manage CRS',
    line_of_therapy: '3L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Very high CR rate comparable or exceeding approved bispecifics', 'Regeneron antibody engineering platform', 'Potential for combination studies'],
    weaknesses: ['Late to market behind Lunsumio and Columvi', 'CRS management complexity', 'Phase 2 single-arm data—needs confirmatory trials'],
    source: 'Regeneron pipeline; ELM-2 (NCT03888105); ASH 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 3. CERVICAL CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Keytruda + chemo',
    generic_name: 'pembrolizumab + paclitaxel/cisplatin ± bevacizumab',
    company: 'Merck',
    indication: 'Cervical Cancer',
    indication_specifics: '1L persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS ≥1',
    mechanism: 'Anti-PD-1 checkpoint inhibitor + cytotoxic chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-826: Keytruda+chemo vs chemo, median OS 28.6 vs 16.5 mo in CPS≥1 (HR 0.64); PFS HR 0.58',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Significant OS and PFS benefit in 1L', 'Established PD-L1 CPS biomarker', 'NCCN Category 1 preferred regimen'],
    weaknesses: ['Requires PD-L1 CPS ≥1 (excludes ~10-15%)', 'Immune-mediated AE burden added to chemo toxicity', 'Benefit attenuated in PD-L1 low/negative subgroups'],
    source: 'FDA label; KEYNOTE-826 (NCT03635567); Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tivdak',
    generic_name: 'tisotumab vedotin-tftv',
    company: 'Seagen/Pfizer',
    indication: 'Cervical Cancer',
    indication_specifics: 'Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy',
    mechanism: 'Anti-tissue factor antibody-drug conjugate (MMAE payload)',
    mechanism_category: 'antibody_drug_conjugate',
    molecular_target: 'Tissue Factor (TF/CD142)',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'innovaTV 204: ORR 24%, median DOR 8.3 mo; innovaTV 301 (2L): OS HR 0.70 vs chemo, confirming benefit',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First ADC approved in cervical cancer', 'Novel tissue factor target universally expressed', 'Confirmed OS benefit in innovaTV 301'],
    weaknesses: ['Ocular toxicity requiring monitoring (conjunctivitis, dry eye)', 'Peripheral neuropathy with MMAE payload', 'Modest ORR as monotherapy'],
    source: 'FDA label; innovaTV 204/301 (NCT03438396/NCT04697628); Pfizer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'HB-201',
    company: 'Hookipa Pharma',
    indication: 'Cervical Cancer',
    indication_specifics: 'HPV16+ recurrent/metastatic HNSCC and cervical cancer',
    mechanism: 'Arenavirus-based immunotherapy expressing HPV16 E6/E7 antigens',
    mechanism_category: 'cancer_vaccine',
    molecular_target: 'HPV16 E6/E7',
    phase: 'Phase 2',
    primary_endpoint: 'ORR',
    key_data: 'HB-200 Phase 1/2: preliminary immune responses and tumor regressions; combination with pembrolizumab enrolling',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Novel viral vector platform with potent T-cell activation', 'Targets HPV oncoproteins driving tumor', 'Potential synergy with checkpoint inhibitors'],
    weaknesses: ['Early clinical data with small patient numbers', 'Limited to HPV16+ tumors (~50% of cervical cancers)', 'Manufacturing complexity of viral vector platform'],
    source: 'Hookipa Pharma pipeline; NCT04180215; ASCO 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 4. ENDOMETRIAL CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Jemperli + chemo',
    generic_name: 'dostarlimab-gxly + carboplatin/paclitaxel',
    company: 'GSK',
    indication: 'Endometrial Cancer',
    indication_specifics: '1L advanced/recurrent endometrial cancer (dMMR/MSI-H and MMRp subsets)',
    mechanism: 'Anti-PD-1 checkpoint inhibitor + platinum-based chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'RUBY Part 1: PFS HR 0.64 overall; dMMR/MSI-H: 24-mo PFS 61.4% vs 15.7% (HR 0.28); OS HR 0.69 overall',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Dramatic benefit in dMMR/MSI-H (~30% of endometrial)', 'First IO+chemo approved for 1L endometrial', 'Benefit across biomarker subgroups (including MMRp)'],
    weaknesses: ['More modest benefit in MMR-proficient tumors', 'Added immune-mediated AEs on top of chemo', 'Premium pricing for broad population use'],
    source: 'FDA label; RUBY (NCT03981796); GSK 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda + Lenvima',
    generic_name: 'pembrolizumab + lenvatinib',
    company: 'Merck/Eisai',
    indication: 'Endometrial Cancer',
    indication_specifics: 'Advanced endometrial cancer not MSI-H/dMMR, after prior platinum chemotherapy',
    mechanism: 'Anti-PD-1 checkpoint inhibitor + multi-kinase TKI (VEGFR/FGFR/PDGFR)',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1 / VEGFR1-3 / FGFR1-4',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-775/Study 309: OS 18.3 vs 11.4 mo (HR 0.62), PFS 7.2 vs 3.8 mo (HR 0.56) vs chemo in non-MSI-H',
    line_of_therapy: '2L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Strong OS and PFS benefit in pMMR population', 'Addresses unmet need in non-MSI-H endometrial', 'Dual mechanism targets tumor and microenvironment'],
    weaknesses: ['Significant toxicity: hypertension (64%), hypothyroidism (57%)', 'Lenvatinib dose reductions frequent (~67%)', 'Complex AE management vs single-agent approaches'],
    source: 'FDA label; KEYNOTE-775 (NCT03517449); Merck/Eisai 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Elahere',
    generic_name: 'mirvetuximab soravtansine-gynx',
    company: 'ImmunoGen/AbbVie',
    indication: 'Endometrial Cancer',
    indication_specifics: 'FRα-high endometrial cancer (under investigation; approved in ovarian)',
    mechanism: 'Anti-folate receptor alpha antibody-drug conjugate (DM4 payload)',
    mechanism_category: 'antibody_drug_conjugate',
    molecular_target: 'FRα (FOLR1)',
    phase: 'Phase 3',
    primary_endpoint: 'PFS',
    key_data: 'FORWARD II endometrial cohort: preliminary ORR ~25% in FRα+ endometrial cancer; Phase 3 enrolling',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Proven ADC platform validated in ovarian cancer', 'Clear biomarker (FRα) for patient selection', 'AbbVie resources post-acquisition of ImmunoGen'],
    weaknesses: ['FRα expression in endometrial lower than ovarian', 'Ocular toxicity (blurred vision, keratopathy)', 'Competing with IO combinations in 2L setting'],
    source: 'AbbVie/ImmunoGen pipeline; FORWARD II (NCT03524534); SGO 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 5. THYROID CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Lenvima',
    generic_name: 'lenvatinib',
    company: 'Eisai',
    indication: 'Thyroid Cancer',
    indication_specifics: 'Locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC',
    mechanism: 'Multi-kinase inhibitor (VEGFR1-3, FGFR1-4, PDGFRα, RET, KIT)',
    mechanism_category: 'tki_multikinase',
    molecular_target: 'VEGFR1-3 / FGFR1-4 / RET / KIT',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'SELECT: median PFS 18.3 vs 3.6 mo placebo (HR 0.21, p<0.001); ORR 64.8% vs 1.5%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Dramatic PFS improvement in RAI-refractory DTC', 'Very high ORR for a TKI', 'Active across multiple thyroid cancer subtypes'],
    weaknesses: ['Hypertension in ~73%, proteinuria, diarrhea', 'Dose reductions required in ~68% of patients', 'No OS benefit demonstrated in SELECT'],
    source: 'FDA label; SELECT (NCT01321554); Eisai 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cabometyx',
    generic_name: 'cabozantinib',
    company: 'Exelixis',
    indication: 'Thyroid Cancer',
    indication_specifics: 'Progressive, metastatic medullary thyroid cancer (MTC)',
    mechanism: 'Multi-kinase inhibitor (MET, VEGFR2, AXL, RET)',
    mechanism_category: 'tki_multikinase',
    molecular_target: 'MET / VEGFR2 / AXL / RET',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'EXAM: median PFS 11.2 vs 4.0 mo placebo (HR 0.28, p<0.001); ORR 28% vs 0%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Standard of care in MTC', 'Active against RET-driven and RET-wild-type MTC', 'Oral dosing with manageable toxicity profile'],
    weaknesses: ['Significant GI toxicity (diarrhea, nausea, decreased appetite)', 'Palmar-plantar erythrodysesthesia', 'Being displaced by selective RET inhibitors in RET-mutant MTC'],
    source: 'FDA label; EXAM (NCT00704730); Exelixis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Gavreto',
    generic_name: 'pralsetinib',
    company: 'Blueprint Medicines/Roche',
    indication: 'Thyroid Cancer',
    indication_specifics: 'Advanced or metastatic RET-mutant MTC and RET fusion-positive thyroid cancer',
    mechanism: 'Selective RET kinase inhibitor',
    mechanism_category: 'ret_inhibitor',
    molecular_target: 'RET',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'ARROW: RET-mutant MTC ORR 60% (prior cabo/vandetanib), 74% (treatment-naive); RET fusion DTC ORR 89%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Highly selective RET inhibitor with excellent ORR', 'Active in both MTC and fusion-positive DTC', 'Favorable toxicity vs multi-kinase TKIs'],
    weaknesses: ['Requires RET mutation/fusion testing for eligibility', 'Blueprint returned US rights to Roche (commercial disruption)', 'Competition from selpercatinib (Retevmo) with head start'],
    source: 'FDA label; ARROW (NCT03037385); Blueprint/Roche 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 6. GLIOBLASTOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Temozolomide',
    generic_name: 'temozolomide',
    company: 'Merck (originator) / Generic',
    indication: 'Glioblastoma',
    indication_specifics: 'Newly diagnosed GBM concurrent with and adjuvant to radiation therapy',
    mechanism: 'Alkylating agent (methylation of DNA at O6-guanine)',
    mechanism_category: 'alkylating_agent',
    molecular_target: 'DNA',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'Stupp regimen: TMZ+RT vs RT, median OS 14.6 vs 12.1 mo; 5-yr OS 9.8% vs 1.9%; MGMT methylated: OS 21.7 mo',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Standard of care for 20+ years (Stupp protocol)', 'MGMT methylation predicts strong benefit', 'Oral formulation with generic availability'],
    weaknesses: ['Modest absolute OS benefit (~2.5 months)', 'Myelosuppression (lymphopenia, thrombocytopenia)', 'Minimal benefit in MGMT-unmethylated GBM'],
    source: 'FDA label; Stupp et al. NEJM 2005; NCCN CNS v2.2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Avastin',
    generic_name: 'bevacizumab',
    company: 'Roche/Genentech',
    indication: 'Glioblastoma',
    indication_specifics: 'Recurrent GBM after prior therapy',
    mechanism: 'Anti-VEGF-A monoclonal antibody (angiogenesis inhibitor)',
    mechanism_category: 'anti_vegf',
    molecular_target: 'VEGF-A',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'AVF3708g: ORR 28.2% (monotherapy), PFS-6 42.6%; no OS benefit in 1L (AVAglio: PFS HR 0.64, OS HR 0.88 NS)',
    line_of_therapy: '2L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Reduces cerebral edema and steroid dependence', 'Meaningful PFS improvement in recurrent GBM', 'Extensive real-world use and physician familiarity'],
    weaknesses: ['No OS benefit in any randomized trial (AVAglio, RTOG 0825)', 'Hypertension, proteinuria, wound healing complications', 'May mask progression on imaging (pseudoresponse)'],
    source: 'FDA label; AVF3708g (NCT00345163); AVAglio (NCT00943826)',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vorasidenib',
    generic_name: 'vorasidenib',
    company: 'Servier',
    indication: 'Glioblastoma',
    indication_specifics: 'Grade 2 IDH-mutant astrocytoma and oligodendroglioma (low-grade glioma)',
    mechanism: 'Dual IDH1/IDH2 mutant enzyme inhibitor (brain-penetrant)',
    mechanism_category: 'idh_inhibitor',
    molecular_target: 'IDH1 / IDH2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'INDIGO: PFS 27.7 vs 11.1 mo (HR 0.39, p<0.001); TTNI HR 0.26; FDA approved Aug 2024 for Grade 2 glioma',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First targeted therapy for IDH-mutant glioma', 'Brain-penetrant dual IDH1/2 inhibitor', 'Dramatic PFS and TTNI improvement in INDIGO'],
    weaknesses: ['Approved for Grade 2, not GBM (Grade 4)—expansion ongoing', 'Elevated liver enzymes requiring monitoring', 'Limited to IDH-mutant subset (~5-10% of GBM)'],
    source: 'FDA label; INDIGO (NCT04164901); Servier 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 7. MESOTHELIOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Opdivo + Yervoy',
    generic_name: 'nivolumab + ipilimumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Mesothelioma',
    indication_specifics: '1L unresectable malignant pleural mesothelioma (MPM)',
    mechanism: 'Anti-PD-1 + anti-CTLA-4 dual checkpoint inhibition',
    mechanism_category: 'checkpoint_inhibitor_combination',
    molecular_target: 'PD-1 / CTLA-4',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate 743: OS 18.1 vs 14.1 mo (HR 0.73, p=0.002); 3-yr OS 23.2% vs 15.4% vs pemetrexed+platinum',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First IO regimen approved in 1L mesothelioma', 'Significant OS advantage over chemotherapy', 'Particular benefit in non-epithelioid histology'],
    weaknesses: ['Dual IO toxicity profile (grade 3+ irAEs ~30%)', 'Epithelioid subtype benefit less pronounced', 'No PFS benefit (co-primary endpoint not met)'],
    source: 'FDA label; CheckMate 743 (NCT02899299); BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Mesothelioma',
    indication_specifics: '1L MPM in combination with pemetrexed and platinum chemotherapy',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 3',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-483: Pembro+chemo vs chemo in 1L MPM; Phase 3 ongoing; IND227 Phase 2: mOS 17.3 mo with Pembro+chemo',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong Keytruda brand and IO+chemo precedent', 'Potentially better tolerability than dual IO approach', 'Extensive Phase 2 data supporting combination'],
    weaknesses: ['No Phase 3 approval yet—behind Opdivo+Yervoy', 'Chemo backbone may limit benefit in non-epithelioid', 'Confirmatory data still pending'],
    source: 'Merck pipeline; KEYNOTE-483 (NCT04153565); IND227',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'ADI-PEG 20',
    generic_name: 'pegargiminase',
    company: 'Polaris Group',
    indication: 'Mesothelioma',
    indication_specifics: '1L non-epithelioid (biphasic and sarcomatoid) MPM',
    mechanism: 'Arginine deiminase—depletes arginine in ASS1-deficient tumors',
    mechanism_category: 'metabolic_enzyme',
    molecular_target: 'Arginine / ASS1',
    phase: 'Phase 3',
    primary_endpoint: 'OS',
    key_data: 'ATOMIC-Meso: ADI-PEG 20+chemo vs chemo, OS 9.3 vs 7.7 mo (HR 0.77, p=0.03) in non-epithelioid MPM',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First-in-class arginine depletion approach', 'Positive Phase 3 OS in non-epithelioid MPM', 'Novel mechanism orthogonal to IO'],
    weaknesses: ['Modest absolute OS benefit (~1.6 months)', 'Allergic reactions to PEGylated enzyme', 'Limited to ASS1-deficient tumors (non-epithelioid enriched)'],
    source: 'Polaris Group; ATOMIC-Meso (NCT02709512); ASCO 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 8. MERKEL CELL CARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Bavencio',
    generic_name: 'avelumab',
    company: 'Merck KGaA/Pfizer',
    indication: 'Merkel Cell Carcinoma',
    indication_specifics: 'Metastatic MCC including 1L and previously treated adults and pediatric ≥12yr',
    mechanism: 'Anti-PD-L1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'JAVELIN Merkel 200: 2L ORR 33.0%, median DOR 40.5 mo; 1L (Part B) ORR 39.7%; durable responses',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First IO approved in MCC', 'Very durable responses (median DOR >3 years)', 'Active regardless of Merkel cell polyomavirus status'],
    weaknesses: ['Requires IV infusion every 2 weeks', 'Infusion-related reactions in ~25%', 'Lower ORR than pembrolizumab in cross-trial comparison'],
    source: 'FDA label; JAVELIN Merkel 200 (NCT02155647); Pfizer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Merkel Cell Carcinoma',
    indication_specifics: 'Recurrent locally advanced or metastatic MCC',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'KEYNOTE-017: 1L ORR 56%, 2-yr PFS 48.3%; CITeR: ORR 58% in real-world 1L; high CR rate ~24%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Higher ORR than avelumab in cross-trial comparisons', 'Strong complete response rate', 'Keytruda brand recognition and Q3W dosing convenience'],
    weaknesses: ['Single-arm Phase 2 data (no randomized comparison)', 'Immune-mediated AEs in ~15-20%', 'No head-to-head data vs avelumab or retifanlimab'],
    source: 'FDA label; KEYNOTE-017 (NCT02267603); NCCN MCC v1.2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zynyz',
    generic_name: 'retifanlimab-dlwr',
    company: 'Incyte',
    indication: 'Merkel Cell Carcinoma',
    indication_specifics: 'Metastatic or recurrent locally advanced MCC',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'POD1UM-201: ORR 52.2%, CR 18%, median DOR not reached; Q4W dosing (every 4 weeks)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Q4W dosing—most convenient dosing schedule in MCC', 'High ORR with durable responses', 'Third PD-1/PD-L1 option provides prescriber choice'],
    weaknesses: ['Late market entry behind Bavencio and Keytruda', 'Single-arm study; limited differentiation from other IOs', 'Incyte smaller commercial footprint than Merck or Pfizer'],
    source: 'FDA label; POD1UM-201 (NCT03599713); Incyte 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 9. CHOLANGIOCARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Pemazyre',
    generic_name: 'pemigatinib',
    company: 'Incyte',
    indication: 'Cholangiocarcinoma',
    indication_specifics: 'Previously treated, unresectable locally advanced or metastatic CCA with FGFR2 fusion or rearrangement',
    mechanism: 'Selective FGFR1/2/3 inhibitor',
    mechanism_category: 'fgfr_inhibitor',
    molecular_target: 'FGFR1 / FGFR2 / FGFR3',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'FIGHT-202: ORR 35.5%, median DOR 7.5 mo in FGFR2 fusion/rearrangement cohort; first targeted CCA approval',
    line_of_therapy: '2L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First targeted therapy approved in CCA', 'Clear biomarker-driven patient selection', 'Oral once-daily dosing'],
    weaknesses: ['Hyperphosphatemia requiring dietary modification', 'Limited to FGFR2 altered subset (~10-15% of iCCA)', 'Serous retinal detachment risk'],
    source: 'FDA label; FIGHT-202 (NCT02924376); Incyte 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Truseltiq',
    generic_name: 'futibatinib',
    company: 'Taiho Oncology',
    indication: 'Cholangiocarcinoma',
    indication_specifics: 'Previously treated, unresectable, locally advanced or metastatic iCCA with FGFR2 gene fusions/rearrangements',
    mechanism: 'Irreversible FGFR1/2/3/4 inhibitor (covalent binding)',
    mechanism_category: 'fgfr_inhibitor',
    molecular_target: 'FGFR1-4',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'FOENIX-CCA2: ORR 42%, median DOR 9.7 mo; active in patients who progressed on prior FGFR inhibitors',
    line_of_therapy: '2L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Irreversible binding may overcome resistance to reversible FGFR inhibitors', 'Higher ORR than pemigatinib in cross-trial comparison', 'Pan-FGFR activity covering all 4 isoforms'],
    weaknesses: ['Hyperphosphatemia and nail toxicity class effects', 'Limited to FGFR2-altered iCCA only', 'Smaller commercial footprint vs Incyte'],
    source: 'FDA label; FOENIX-CCA2 (NCT02052778); Taiho 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tibsovo',
    generic_name: 'ivosidenib',
    company: 'Servier',
    indication: 'Cholangiocarcinoma',
    indication_specifics: 'Previously treated, locally advanced or metastatic CCA with IDH1 mutation',
    mechanism: 'IDH1 mutant enzyme inhibitor',
    mechanism_category: 'idh_inhibitor',
    molecular_target: 'IDH1',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ClarIDHy: PFS 2.7 vs 1.4 mo (HR 0.37, p<0.001); OS 10.3 vs 7.5 mo with crossover adjustment',
    line_of_therapy: '2L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First IDH1 inhibitor approved in solid tumors', 'Statistically significant PFS and OS benefit', 'Well-tolerated oral once-daily dosing'],
    weaknesses: ['Modest absolute PFS improvement', 'Limited to IDH1-mutant subset (~13% of iCCA)', 'QTc prolongation risk requiring ECG monitoring'],
    source: 'FDA label; ClarIDHy (NCT02989857); Servier 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 10. ADRENOCORTICAL CARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Lysodren',
    generic_name: 'mitotane',
    company: 'HRA Pharma',
    indication: 'Adrenocortical Carcinoma',
    indication_specifics: 'Inoperable, functional and non-functional adrenocortical carcinoma',
    mechanism: 'Adrenolytic agent—causes adrenal cortex necrosis and modifies steroid metabolism',
    mechanism_category: 'adrenolytic_agent',
    molecular_target: 'Adrenal cortex mitochondria',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'Historical data: ORR 13-35% (variable criteria), controls cortisol hypersecretion; ADIUVO adjuvant trial: RFS HR 0.74 (NS)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Only approved drug specifically for ACC', 'Controls hormone excess in functional ACC', 'Decades of clinical experience'],
    weaknesses: ['Narrow therapeutic window (plasma levels 14-20 mg/L needed)', 'Severe GI and neurological toxicity', 'Slow onset of action (months to therapeutic levels)'],
    source: 'FDA label; ADIUVO trial; ESMO ACC guidelines 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'ATR-101',
    generic_name: 'nevanimibe',
    company: 'Millendo Therapeutics',
    indication: 'Adrenocortical Carcinoma',
    indication_specifics: 'Advanced ACC and endogenous Cushing syndrome',
    mechanism: 'ACAT1 (acyl-CoA:cholesterol acyltransferase 1) inhibitor',
    mechanism_category: 'metabolic_inhibitor',
    molecular_target: 'ACAT1',
    phase: 'Phase 2',
    primary_endpoint: 'ORR',
    key_data: 'Phase 2: dose-escalation study showing adrenal steroid reduction; limited efficacy data published; development status uncertain',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Novel mechanism distinct from mitotane', 'Targets cholesterol metabolism in adrenal tumors', 'Orphan drug designation'],
    weaknesses: ['Very early clinical data with uncertain development timeline', 'Millendo merged with OvaScience—development continuity concerns', 'Narrow indication with limited commercial potential'],
    source: 'Millendo Therapeutics; NCT03053271; AACR 2019',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Adrenocortical Carcinoma',
    indication_specifics: 'Advanced ACC after prior mitotane ± chemotherapy',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 2',
    primary_endpoint: 'ORR',
    key_data: 'KEYNOTE-158 ACC cohort: ORR 23.1% (6/26 patients), median PFS 2.1 mo; some durable responses >12 mo',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Meaningful responses in subset of ACC patients', 'Immune checkpoint approach may benefit MSI-H ACC subset', 'Broad Keytruda access and familiarity'],
    weaknesses: ['Low overall ORR (23%) in unselected ACC', 'Short median PFS suggesting most patients progress', 'No randomized data in ACC—single-arm Phase 2'],
    source: 'Merck; KEYNOTE-158 (NCT02628067); JCO 2020',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 11. MANTLE CELL LYMPHOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Calquence',
    generic_name: 'acalabrutinib',
    company: 'AstraZeneca',
    indication: 'Mantle Cell Lymphoma',
    indication_specifics: 'R/R MCL after at least one prior therapy',
    mechanism: 'Second-generation selective BTK inhibitor (covalent)',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'ACE-LY-004: ORR 81%, CR 40%, median DOR 28.6 mo; improved selectivity over ibrutinib',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['High ORR with durable responses', 'More selective BTK binding—fewer off-target cardiac AEs than ibrutinib', 'Twice-daily oral dosing well tolerated'],
    weaknesses: ['Atrial fibrillation still occurs (~5-7%)', 'Resistance develops through BTK C481S mutation', 'No head-to-head superiority data vs ibrutinib in MCL'],
    source: 'FDA label; ACE-LY-004 (NCT02213926); AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Brukinsa',
    generic_name: 'zanubrutinib',
    company: 'BeiGene',
    indication: 'Mantle Cell Lymphoma',
    indication_specifics: 'R/R MCL after at least one prior therapy',
    mechanism: 'Next-generation selective BTK inhibitor (covalent)',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'BGB-3111-206: ORR 83.7%, CR 77.9%, median DOR not reached; ALPINE: superior PFS vs ibrutinib in CLL',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Very high CR rate in MCL', 'Lowest atrial fibrillation rate among BTK inhibitors', 'ALPINE demonstrated superiority over ibrutinib in CLL'],
    weaknesses: ['BeiGene smaller commercial footprint in US/EU', 'Resistance via BTK C481S mutation similar to class', 'Crowded BTK inhibitor space in MCL'],
    source: 'FDA label; BGB-3111-206 (NCT03206970); BeiGene 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Jaypirca',
    generic_name: 'pirtobrutinib',
    company: 'Eli Lilly',
    indication: 'Mantle Cell Lymphoma',
    indication_specifics: 'R/R MCL after at least two prior lines including a BTK inhibitor',
    mechanism: 'Non-covalent (reversible) BTK inhibitor',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Phase 3',
    primary_endpoint: 'ORR',
    key_data: 'BRUIN: ORR 57.8%, CR 20.5% in MCL post-covalent BTK inhibitor; active despite C481S resistance mutations',
    line_of_therapy: '3L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Active after covalent BTK inhibitor failure (C481S resistant)', 'First non-covalent BTK inhibitor—addresses resistance', 'Well-tolerated with low discontinuation rate'],
    weaknesses: ['Lower ORR than covalent BTKi in BTK-naive patients', 'Accelerated approval—confirmatory BRUIN-MCL-321 Phase 3 ongoing', 'Median DOR ~17.6 mo—some patients still progress'],
    source: 'FDA label; BRUIN (NCT03740529); Eli Lilly 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 12. MYELODYSPLASTIC SYNDROMES
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Vidaza',
    generic_name: 'azacitidine',
    company: 'Bristol-Myers Squibb',
    indication: 'Myelodysplastic Syndromes',
    indication_specifics: 'Higher-risk MDS (IPSS Int-2, High) — all FAB subtypes',
    mechanism: 'Hypomethylating agent (DNA methyltransferase inhibitor)',
    mechanism_category: 'hypomethylating_agent',
    molecular_target: 'DNMT1 / DNMT3',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'AZA-001: OS 24.5 vs 15.0 mo (HR 0.58, p=0.0001); CR 17%; transfusion independence 45% vs 11.4%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Only drug to demonstrate OS benefit in higher-risk MDS', 'Standard of care for HR-MDS worldwide', 'Subcutaneous administration in outpatient setting'],
    weaknesses: ['Myelosuppression (neutropenia, thrombocytopenia)', 'Continuous therapy required—no curative intent', 'Response often wanes after 12-18 months'],
    source: 'FDA label; AZA-001 (NCT00071799); NCCN MDS v1.2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Revlimid',
    generic_name: 'lenalidomide',
    company: 'Bristol-Myers Squibb',
    indication: 'Myelodysplastic Syndromes',
    indication_specifics: 'Transfusion-dependent anemia in low/Int-1-risk MDS with del(5q) ± additional cytogenetic abnormalities',
    mechanism: 'Immunomodulatory agent (cereblon E3 ligase modulator, degradation of CK1α)',
    mechanism_category: 'immunomodulatory',
    molecular_target: 'Cereblon / CK1α',
    phase: 'Approved',
    primary_endpoint: 'Transfusion independence',
    key_data: 'MDS-004: TI rate 56.1% (10mg) vs 5.9% placebo; cytogenetic response 50%; median DOR 2+ years in del(5q)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Dramatic responses in del(5q) MDS population', 'High transfusion independence rate', 'Oral once-daily dosing'],
    weaknesses: ['Limited to del(5q) subset (~10-15% of MDS)', 'Teratogenicity requiring REMS program', 'Neutropenia and thrombocytopenia common (dose reductions in ~50%)'],
    source: 'FDA label; MDS-004 (NCT00179621); BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rytelo',
    generic_name: 'imetelstat',
    company: 'Geron Corporation',
    indication: 'Myelodysplastic Syndromes',
    indication_specifics: 'Low/Int-1 risk MDS with transfusion-dependent anemia relapsed/refractory to ESAs',
    mechanism: 'Telomerase inhibitor (first-in-class oligonucleotide targeting hTERT RNA template)',
    mechanism_category: 'telomerase_inhibitor',
    molecular_target: 'hTERT',
    phase: 'Approved',
    primary_endpoint: 'Transfusion independence',
    key_data: 'IMerge Phase 3: 8-wk TI 39.8% vs 15% placebo (p<0.001); 24-wk TI 28.0% vs 3.3%; RBC-TI durable',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First telomerase inhibitor approved in any indication', 'Novel mechanism for ESA-refractory LR-MDS patients', 'Addresses clear unmet need after ESA failure'],
    weaknesses: ['IV infusion every 4 weeks', 'Cytopenias (grade 3+ neutropenia, thrombocytopenia)', 'Liver enzyme elevations requiring monitoring'],
    source: 'FDA label; IMerge (NCT02598661); Geron 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 13. MYELOFIBROSIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Jakafi',
    generic_name: 'ruxolitinib',
    company: 'Incyte',
    indication: 'Myelofibrosis',
    indication_specifics: 'Intermediate or high-risk myelofibrosis including primary MF, post-PV MF, and post-ET MF',
    mechanism: 'JAK1/JAK2 inhibitor',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1 / JAK2',
    phase: 'Approved',
    primary_endpoint: 'SVR35',
    key_data: 'COMFORT-I/II: SVR35 at 24 wk 41.9% vs 0.7% placebo; OS HR 0.69 at 5 yr; symptom improvement in >50%',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First JAK inhibitor approved—established standard of care', 'Demonstrated spleen and symptom improvement', 'Long-term OS benefit in COMFORT studies'],
    weaknesses: ['Anemia and thrombocytopenia dose-limiting', 'Disease progression on therapy with clonal evolution', 'Weight gain and opportunistic infections (herpes zoster)'],
    source: 'FDA label; COMFORT-I (NCT00952289); Incyte 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vonjo',
    generic_name: 'pacritinib',
    company: 'CTI BioPharma',
    indication: 'Myelofibrosis',
    indication_specifics: 'Intermediate or high-risk MF with platelet count <50×10⁹/L (severely cytopenic)',
    mechanism: 'JAK2/IRAK1 inhibitor (minimal JAK1 inhibition)',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK2 / IRAK1',
    phase: 'Approved',
    primary_endpoint: 'SVR35',
    key_data: 'PERSIST-2: SVR35 18% vs 3% BAT in patients with platelets <50K; safe in severe thrombocytopenia',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Only JAK inhibitor approved for severely cytopenic MF (platelets <50K)', 'Spares JAK1—less immunosuppression', 'Fills critical unmet need for patients ineligible for ruxolitinib'],
    weaknesses: ['FDA full clinical hold history delayed development', 'Cardiac AE monitoring required (QTc)', 'GI toxicity (diarrhea, nausea) common'],
    source: 'FDA label; PERSIST-2 (NCT02055781); CTI BioPharma 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ojjaara',
    generic_name: 'momelotinib',
    company: 'GSK',
    indication: 'Myelofibrosis',
    indication_specifics: 'MF with anemia in patients previously treated with a JAK inhibitor and JAK inhibitor-naive',
    mechanism: 'JAK1/JAK2/ACVR1 inhibitor (ACVR1 drives anemia benefit)',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1 / JAK2 / ACVR1',
    phase: 'Approved',
    primary_endpoint: 'TSS50',
    key_data: 'MOMENTUM: TSS50 25% vs 9% danazol; TI rate 30% vs 20%; SVR35 23% vs 3%; unique anemia benefit via ACVR1',
    line_of_therapy: '2L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Unique ACVR1 inhibition improves anemia (hepcidin-mediated)', 'Triple benefit: spleen + symptoms + anemia', 'Addresses key limitation of ruxolitinib (worsens anemia)'],
    weaknesses: ['Peripheral neuropathy (new-onset or worsening in ~10%)', 'Modest SVR35 rate vs ruxolitinib', 'Late market entry in increasingly competitive JAK inhibitor space'],
    source: 'FDA label; MOMENTUM (NCT04173494); GSK 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 14. POLYCYTHEMIA VERA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Jakafi',
    generic_name: 'ruxolitinib',
    company: 'Incyte',
    indication: 'Polycythemia Vera',
    indication_specifics: 'PV with inadequate response to or intolerance of hydroxyurea',
    mechanism: 'JAK1/JAK2 inhibitor',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1 / JAK2',
    phase: 'Approved',
    primary_endpoint: 'Hematocrit control',
    key_data: 'RESPONSE: Hct control+spleen reduction 22.7% vs 0.9% BAT at 32 wk; 5-yr complete hematologic remission 24%',
    line_of_therapy: '2L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First targeted therapy approved for PV', 'Durable hematocrit and symptom control', 'Reduces phlebotomy requirement'],
    weaknesses: ['Anemia, thrombocytopenia, weight gain', 'Herpes zoster reactivation risk', 'Does not eliminate the malignant clone in most patients'],
    source: 'FDA label; RESPONSE (NCT01243944); Incyte 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Besremi',
    generic_name: 'ropeginterferon alfa-2b',
    company: 'PharmaEssentia',
    indication: 'Polycythemia Vera',
    indication_specifics: '1L and 2L PV in adults (first biologic approved for PV)',
    mechanism: 'PEGylated interferon alfa-2b — targets JAK2-mutant clone selectively',
    mechanism_category: 'interferon',
    molecular_target: 'IFNAR1/IFNAR2',
    phase: 'Approved',
    primary_endpoint: 'Complete hematologic response',
    key_data: 'PROUD-PV/CONTINUATION-PV: CHR 53% vs 38% HU at 36 mo; molecular response (JAK2 VAF reduction) 66% at 5 yr',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Disease-modifying: reduces JAK2 allele burden', 'Approved for 1L—can be used before HU', 'Q2W SC injection with potential for monthly dosing'],
    weaknesses: ['Interferon class AEs: flu-like symptoms, depression, fatigue', 'Autoimmune complications in ~5-10%', 'Slow onset of molecular response (months to years)'],
    source: 'FDA label; PROUD-PV (NCT01949805); PharmaEssentia 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Givinostat',
    generic_name: 'givinostat',
    company: 'Italfarmaco',
    indication: 'Polycythemia Vera',
    indication_specifics: 'PV patients with inadequate response to or intolerance of hydroxyurea',
    mechanism: 'Pan-histone deacetylase (HDAC) inhibitor',
    mechanism_category: 'hdac_inhibitor',
    molecular_target: 'HDAC Class I and II',
    phase: 'Phase 3',
    primary_endpoint: 'Spleen response + symptom control',
    key_data: 'ESSENTIAL Phase 3: pending results; Phase 1/2: spleen response rate ~50%, JAK2 VAF reduction in some patients',
    line_of_therapy: '2L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Novel oral HDAC inhibitor mechanism for PV', 'Potential synergy with ruxolitinib or interferon', 'Disease-modifying potential via epigenetic reprogramming'],
    weaknesses: ['Phase 3 data not yet reported', 'HDAC inhibitor class toxicity (GI, thrombocytopenia, fatigue)', 'Italfarmaco limited oncology commercial presence'],
    source: 'Italfarmaco pipeline; ESSENTIAL (NCT04551066); EHA 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 15. NEUROBLASTOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Unituxin',
    generic_name: 'dinutuximab',
    company: 'United Therapeutics',
    indication: 'Neuroblastoma',
    indication_specifics: 'High-risk neuroblastoma in pediatric patients achieving at least partial response to prior therapy',
    mechanism: 'Anti-GD2 monoclonal antibody (chimeric) — mediates ADCC and CDC',
    mechanism_category: 'monoclonal_antibody',
    molecular_target: 'GD2',
    phase: 'Approved',
    primary_endpoint: 'EFS',
    key_data: 'ANBL0032: 2-yr EFS 66% vs 46% (p=0.01) with immunotherapy (dinutuximab+IL-2+GM-CSF+RA) vs isotretinoin alone',
    line_of_therapy: 'maintenance',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Significant EFS and OS improvement in high-risk neuroblastoma', 'Anti-GD2 immunotherapy established as standard of care', 'GD2 highly expressed on neuroblastoma cells'],
    weaknesses: ['Severe neuropathic pain requiring opioid management', 'Requires co-administration with IL-2, GM-CSF, isotretinoin', 'Capillary leak syndrome and hypotension risk'],
    source: 'FDA label; ANBL0032 (NCT00026312); United Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Danyelza',
    generic_name: 'naxitamab-gqgk',
    company: 'Y-mAbs Therapeutics',
    indication: 'Neuroblastoma',
    indication_specifics: 'R/R high-risk neuroblastoma in bone or bone marrow, with inadequate response to prior therapy',
    mechanism: 'Anti-GD2 humanized monoclonal antibody (with GM-CSF)',
    mechanism_category: 'monoclonal_antibody',
    molecular_target: 'GD2',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'Study 201: ORR 45% (CR 34%) in R/R neuroblastoma with bone/bone marrow disease; median DOR not reached',
    line_of_therapy: '3L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Humanized antibody—potentially less immunogenicity vs chimeric', 'High CR rate in bone/BM disease', 'Outpatient-compatible infusion schedule'],
    weaknesses: ['Accelerated approval—confirmatory trial needed', 'Severe infusion-related pain and reactions', 'Narrow indication (bone/BM only, not soft tissue)'],
    source: 'FDA label; Study 201 (NCT03363373); Y-mAbs 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'DFMO',
    generic_name: 'eflornithine',
    company: 'US WorldMeds',
    indication: 'Neuroblastoma',
    indication_specifics: 'High-risk neuroblastoma maintenance after completion of multiagent/multimodality therapy with at least PR',
    mechanism: 'Irreversible ornithine decarboxylase (ODC) inhibitor—blocks polyamine synthesis',
    mechanism_category: 'metabolic_inhibitor',
    molecular_target: 'Ornithine decarboxylase (ODC)',
    phase: 'Approved',
    primary_endpoint: 'EFS',
    key_data: 'ANBL1232: EFS HR 0.57 (p=0.0029) for DFMO maintenance; 2-yr EFS 84% vs 73.5% vs observation; oral dosing',
    line_of_therapy: 'maintenance',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Oral maintenance therapy—convenient for pediatric patients', 'Significant EFS improvement in maintenance setting', 'Novel polyamine pathway targeting'],
    weaknesses: ['Ototoxicity (hearing loss) in ~17%', 'GI side effects (diarrhea, nausea)', 'Limited to maintenance setting—no activity in active relapse'],
    source: 'FDA label; ANBL1232 (NCT02395666); US WorldMeds 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 16. EWING SARCOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'VDC/IE',
    generic_name: 'vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide',
    company: 'Generic',
    indication: 'Ewing Sarcoma',
    indication_specifics: 'Localized and metastatic Ewing sarcoma, first-line multi-agent chemotherapy',
    mechanism: 'Cytotoxic combination chemotherapy (alkylating agents + topoisomerase inhibitor + vinca alkaloid)',
    mechanism_category: 'cytotoxic_chemotherapy',
    phase: 'Approved',
    primary_endpoint: 'EFS',
    key_data: 'AEWS0031: Q2W compressed schedule 5-yr EFS 73% vs 65% Q3W (p=0.048); standard backbone for 30+ years',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Established standard of care for decades', 'Curative in ~65-70% of localized Ewing sarcoma', 'Compressed Q2W schedule improves outcomes'],
    weaknesses: ['Severe myelosuppression requiring growth factor support', 'Cardiotoxicity from doxorubicin (cumulative dose limit)', 'No targeted therapy component—brute force approach'],
    source: 'NCCN Bone Cancer v1.2024; AEWS0031 (NCT00006734); COG protocols',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Yondelis',
    generic_name: 'trabectedin',
    company: 'PharmaMar',
    indication: 'Ewing Sarcoma',
    indication_specifics: 'R/R Ewing sarcoma after failure of standard chemotherapy',
    mechanism: 'Minor groove DNA binder—inhibits transcription factor binding and DNA repair (TC-NER)',
    mechanism_category: 'dna_binding_agent',
    molecular_target: 'DNA minor groove / TC-NER',
    phase: 'Phase 2',
    primary_endpoint: 'PFS',
    key_data: 'Phase 2 studies: ORR 10-15% in R/R Ewing sarcoma; PFS-6 ~20-30%; approved in STS but investigational in Ewing',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Unique DNA-binding mechanism not cross-resistant with standard chemo', 'Approved drug in STS—known safety profile', 'Active against EWS-FLI1 transcription factor biology'],
    weaknesses: ['Modest single-agent activity in Ewing sarcoma', 'Hepatotoxicity requiring liver function monitoring', 'IV infusion over 24 hours—logistically burdensome'],
    source: 'PharmaMar; NCT01426633; ESMO STS guidelines 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Seclidemstat',
    generic_name: 'seclidemstat',
    company: 'Salarius Pharmaceuticals',
    indication: 'Ewing Sarcoma',
    indication_specifics: 'R/R Ewing sarcoma and FET-rearranged sarcomas',
    mechanism: 'Reversible LSD1 (lysine-specific demethylase 1) inhibitor—disrupts EWS-FLI1 oncogenic transcription',
    mechanism_category: 'epigenetic_inhibitor',
    molecular_target: 'LSD1 (KDM1A)',
    phase: 'Phase 1/2',
    primary_endpoint: 'ORR',
    key_data: 'Phase 1/2 SEISMIC: dose escalation complete; disease control rate ~40% in evaluable Ewing sarcoma patients',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Directly targets EWS-FLI1 dependency via LSD1', 'Oral once-daily dosing', 'First-in-class for Ewing sarcoma—high unmet need'],
    weaknesses: ['Early-phase data with small sample sizes', 'Dysgeusia and myelosuppression dose-limiting toxicities', 'Salarius small company with limited resources'],
    source: 'Salarius Pharma; SEISMIC (NCT03600649); ASCO 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 17. OSTEOSARCOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'MAP regimen',
    generic_name: 'high-dose methotrexate + doxorubicin (Adriamycin) + cisplatin',
    company: 'Generic',
    indication: 'Osteosarcoma',
    indication_specifics: 'Newly diagnosed localized high-grade osteosarcoma, neoadjuvant and adjuvant',
    mechanism: 'Multi-agent cytotoxic chemotherapy (antifolate + anthracycline + platinum)',
    mechanism_category: 'cytotoxic_chemotherapy',
    phase: 'Approved',
    primary_endpoint: 'EFS',
    key_data: 'EURAMOS-1: 5-yr EFS 59-61% with MAP; histologic response (≥90% necrosis) in ~40% predicts outcome; adding ifosfamide/etoposide did not improve EFS',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Curative in ~60% of localized osteosarcoma', 'Established standard for 40+ years', 'Histologic response guides prognosis'],
    weaknesses: ['No improvement in outcomes since 1980s', 'High-dose methotrexate requires therapeutic drug monitoring', 'Severe toxicity: nephrotoxicity, cardiotoxicity, ototoxicity'],
    source: 'NCCN Bone Cancer v1.2024; EURAMOS-1 (NCT00134030)',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Mepact',
    generic_name: 'mifamurtide',
    company: 'Takeda',
    indication: 'Osteosarcoma',
    indication_specifics: 'Non-metastatic resectable high-grade osteosarcoma after complete surgical resection (adjuvant, EU-approved)',
    mechanism: 'Muramyl tripeptide—macrophage/monocyte activator (innate immune stimulant)',
    mechanism_category: 'immune_stimulant',
    molecular_target: 'NOD2 (innate immune receptor)',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'INT-0133: 6-yr OS 78% vs 70% with mifamurtide added to chemo (p=0.03); EFS benefit not statistically significant',
    line_of_therapy: 'adjuvant',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Only immunotherapy approved for osteosarcoma (EU)', 'Significant OS benefit in adjuvant setting', 'Novel innate immune activation mechanism'],
    weaknesses: ['Not FDA-approved (only EMA)—availability limited', 'Chills, fever, fatigue with infusions', 'No benefit in metastatic osteosarcoma'],
    source: 'EMA label; INT-0133 (NCT00006117); Takeda 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cabometyx',
    generic_name: 'cabozantinib',
    company: 'Exelixis',
    indication: 'Osteosarcoma',
    indication_specifics: 'R/R osteosarcoma after failure of standard chemotherapy',
    mechanism: 'Multi-kinase inhibitor (MET, VEGFR2, AXL, RET)',
    mechanism_category: 'tki_multikinase',
    molecular_target: 'MET / VEGFR2 / AXL / RET',
    phase: 'Phase 2',
    primary_endpoint: 'ORR',
    key_data: 'CABONE/SARCOME-13: Phase 2 ORR 12%, PFS-6 33% in R/R osteosarcoma; modest but notable in refractory setting',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Oral multikinase TKI with anti-angiogenic and MET activity', 'NCCN listed as option for R/R osteosarcoma', 'Already approved in other indications—known safety profile'],
    weaknesses: ['Low ORR (~12%) in osteosarcoma', 'Fatigue, hand-foot syndrome, diarrhea', 'Not specifically approved for osteosarcoma'],
    source: 'Exelixis; CABONE (NCT02243605); NCCN Bone Cancer v1.2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 18. SOFT TISSUE SARCOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Yondelis',
    generic_name: 'trabectedin',
    company: 'PharmaMar',
    indication: 'Soft Tissue Sarcoma',
    indication_specifics: 'Unresectable or metastatic liposarcoma or leiomyosarcoma after prior anthracycline-containing regimen',
    mechanism: 'Minor groove DNA binder—inhibits activated transcription and poisons TC-NER DNA repair',
    mechanism_category: 'dna_binding_agent',
    molecular_target: 'DNA minor groove / TC-NER',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ET743-SAR-3007: PFS 4.2 vs 1.5 mo dacarbazine (HR 0.55, p<0.001); OS 12.4 vs 12.9 mo (NS); LPS benefit strongest',
    line_of_therapy: '2L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Significant PFS improvement in L-sarcomas', 'Unique mechanism of action for sarcoma', 'Particularly active in myxoid liposarcoma'],
    weaknesses: ['No OS benefit over dacarbazine', '24-hour IV infusion—logistically demanding', 'Hepatotoxicity and neutropenia common'],
    source: 'FDA label; ET743-SAR-3007 (NCT01343277); PharmaMar 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Votrient',
    generic_name: 'pazopanib',
    company: 'Novartis',
    indication: 'Soft Tissue Sarcoma',
    indication_specifics: 'Advanced STS previously treated with chemotherapy (excludes adipocytic STS and GIST)',
    mechanism: 'Multi-kinase inhibitor (VEGFR1-3, PDGFRα/β, FGFR1/3, c-KIT)',
    mechanism_category: 'tki_multikinase',
    molecular_target: 'VEGFR1-3 / PDGFR / c-KIT',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'PALETTE: PFS 4.6 vs 1.6 mo placebo (HR 0.31, p<0.001); no OS benefit; active across multiple STS subtypes',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Oral TKI with broad STS activity', 'Significant PFS improvement over placebo', 'Convenient once-daily oral dosing'],
    weaknesses: ['No OS benefit demonstrated', 'Hepatotoxicity (liver function monitoring required)', 'Hypertension, diarrhea, fatigue common'],
    source: 'FDA label; PALETTE (NCT00753688); Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Halaven',
    generic_name: 'eribulin mesylate',
    company: 'Eisai',
    indication: 'Soft Tissue Sarcoma',
    indication_specifics: 'Unresectable or metastatic liposarcoma after prior anthracycline-containing regimen',
    mechanism: 'Microtubule dynamics inhibitor (halichondrin B analog—non-taxane tubulin inhibitor)',
    mechanism_category: 'microtubule_inhibitor',
    molecular_target: 'Tubulin (microtubule plus ends)',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'Study 309: OS 15.6 vs 8.4 mo dacarbazine in liposarcoma (HR 0.51); no benefit in leiomyosarcoma (OS HR 0.93)',
    line_of_therapy: '2L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Significant OS benefit in liposarcoma (7+ month improvement)', 'Only drug with OS benefit in STS subtype', 'Known safety profile from breast cancer use'],
    weaknesses: ['Benefit limited to liposarcoma—no benefit in leiomyosarcoma', 'Neutropenia and peripheral neuropathy', 'IV administration (2-5 minute infusion Days 1,8 of 21-day cycle)'],
    source: 'FDA label; Study 309 (NCT01327885); Eisai 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 19. ESOPHAGEAL CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Opdivo + chemo',
    generic_name: 'nivolumab + fluoropyrimidine/platinum chemotherapy',
    company: 'Bristol-Myers Squibb',
    indication: 'Esophageal Cancer',
    indication_specifics: '1L advanced/metastatic esophageal squamous cell carcinoma (ESCC) and GEJ adenocarcinoma',
    mechanism: 'Anti-PD-1 checkpoint inhibitor + cytotoxic chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate 648: OS 15.4 vs 9.1 mo in PD-L1 TPS≥1 ESCC (HR 0.54); CheckMate 649: GEJ OS HR 0.71 in PD-L1 CPS≥5',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Significant OS benefit in esophageal and GEJ cancers', 'Active in both squamous and adenocarcinoma histologies', 'Nivolumab also approved in adjuvant (CheckMate 577)'],
    weaknesses: ['Benefit concentrated in PD-L1 positive subgroups', 'Added immune-mediated toxicity burden', 'Multiple competing IO+chemo regimens in same space'],
    source: 'FDA label; CheckMate 648 (NCT03143153); BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Esophageal Cancer',
    indication_specifics: '1L locally advanced/metastatic esophageal or GEJ cancer with CPS ≥10',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-590: OS 13.9 vs 9.8 mo with pembro+chemo in CPS≥10 (HR 0.62); ORR 51.1% vs 26.9%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Strong OS benefit in PD-L1 CPS≥10 population', 'Keytruda brand and broad oncology familiarity', 'Active across esophageal SCC and adenocarcinoma'],
    weaknesses: ['CPS≥10 cutoff excludes substantial patient population', 'Competing directly with Opdivo+chemo in same setting', 'IO-related AEs in combination with chemo'],
    source: 'FDA label; KEYNOTE-590 (NCT03189719); Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tevimbra',
    generic_name: 'tislelizumab',
    company: 'BeiGene',
    indication: 'Esophageal Cancer',
    indication_specifics: 'Unresectable, recurrent, locally advanced or metastatic ESCC after prior platinum-based chemotherapy',
    mechanism: 'Anti-PD-1 checkpoint inhibitor (Fc-null to minimize FcγR binding on macrophages)',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'RATIONALE 302: OS 8.6 vs 6.3 mo vs chemo in 2L ESCC (HR 0.70, p=0.0001); also 1L RATIONALE 306 positive',
    line_of_therapy: '2L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Fc-null design may reduce T-cell elimination by macrophages', 'Approved in both 1L and 2L ESCC settings globally', 'Competitive pricing strategy from BeiGene'],
    weaknesses: ['Later US market entry behind Opdivo and Keytruda', 'Differentiation from other PD-1s not clearly established', 'BeiGene building US commercial infrastructure'],
    source: 'FDA label; RATIONALE 302 (NCT03430843); BeiGene 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 20. HODGKIN LYMPHOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Adcetris',
    generic_name: 'brentuximab vedotin',
    company: 'Seagen/Pfizer',
    indication: 'Hodgkin Lymphoma',
    indication_specifics: '1L Stage III/IV cHL in combination with AVD; also R/R cHL post-ASCT or post-2 prior regimens',
    mechanism: 'Anti-CD30 antibody-drug conjugate (MMAE payload)',
    mechanism_category: 'antibody_drug_conjugate',
    molecular_target: 'CD30',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ECHELON-1: 6-yr PFS 82.3% vs 74.5% with A+AVD vs ABVD (HR 0.68); established as 1L standard in Stage III/IV',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['PFS improvement over ABVD in 1L Stage III/IV', 'CD30 universally expressed on Hodgkin Reed-Sternberg cells', 'Multiple approved indications across HL treatment lines'],
    weaknesses: ['Peripheral neuropathy from MMAE payload (in ~67%)', 'Higher rate of neutropenia than ABVD requiring G-CSF', 'Premium pricing over generic ABVD'],
    source: 'FDA label; ECHELON-1 (NCT01712490); Pfizer/Seagen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Opdivo',
    generic_name: 'nivolumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Hodgkin Lymphoma',
    indication_specifics: 'R/R cHL after ASCT and post-transplant brentuximab vedotin, or 3+ prior lines including ASCT',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'CheckMate 205: ORR 69%, CR 16%, median DOR 16.6 mo; active in heavily pretreated cHL',
    line_of_therapy: '3L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['High ORR in heavily pretreated cHL', 'cHL has 9p24.1 amplification making it IO-sensitive', 'Can bridge to allogeneic transplant'],
    weaknesses: ['Not curative as monotherapy—most patients eventually progress', 'Immune-mediated AEs may complicate subsequent allo-SCT', 'Continuous therapy until progression or toxicity'],
    source: 'FDA label; CheckMate 205 (NCT02181738); BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Hodgkin Lymphoma',
    indication_specifics: 'R/R cHL after 3+ prior lines; also 1L with cHL (KEYNOTE-204 vs brentuximab vedotin)',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'KEYNOTE-087: ORR 69.0%, CR 22.4% in R/R cHL; KEYNOTE-204: PFS HR 0.65 vs brentuximab vedotin in 2L+',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Superior PFS vs brentuximab vedotin in KEYNOTE-204', 'High ORR with CR rate >22%', 'Q3W or Q6W dosing convenience'],
    weaknesses: ['Limited long-term data on durability vs brentuximab vedotin', 'irAEs may complicate transplant eligibility', 'Competes with Opdivo in same R/R space'],
    source: 'FDA label; KEYNOTE-087 (NCT02453594); Merck 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 21. CHRONIC MYELOID LEUKEMIA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Gleevec',
    generic_name: 'imatinib mesylate',
    company: 'Novartis',
    indication: 'Chronic Myeloid Leukemia',
    indication_specifics: 'Newly diagnosed Philadelphia chromosome-positive CML in chronic phase',
    mechanism: 'BCR-ABL1 tyrosine kinase inhibitor (first-generation TKI)',
    mechanism_category: 'bcr_abl_inhibitor',
    molecular_target: 'BCR-ABL1',
    phase: 'Approved',
    primary_endpoint: 'MMR',
    key_data: 'IRIS: 10-yr OS 83.3%; CCyR 82.8%; transformed CML treatment from fatal to chronic disease; generic since 2016',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Revolutionized CML treatment—near-normal life expectancy', 'Generic availability—low cost', '20+ years of real-world safety data'],
    weaknesses: ['Slower/shallower responses vs 2G TKIs', 'GI side effects, edema, muscle cramps', 'Not recommended for high-risk or accelerated/blast phase'],
    source: 'FDA label; IRIS (NCT00006343); Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Sprycel',
    generic_name: 'dasatinib',
    company: 'Bristol-Myers Squibb',
    indication: 'Chronic Myeloid Leukemia',
    indication_specifics: 'Newly diagnosed CP-CML (1L) and CML resistant/intolerant to imatinib (2L+)',
    mechanism: 'BCR-ABL1/SRC family kinase inhibitor (second-generation TKI)',
    mechanism_category: 'bcr_abl_inhibitor',
    molecular_target: 'BCR-ABL1 / SRC',
    phase: 'Approved',
    primary_endpoint: 'MMR',
    key_data: 'DASISION: 5-yr MMR 76% vs 64% imatinib; faster and deeper responses; 5-yr OS 91% vs 90%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Deeper and faster molecular responses vs imatinib', 'Active against most imatinib-resistant BCR-ABL mutations', 'Once-daily dosing'],
    weaknesses: ['Pleural effusion in ~28% (unique class AE)', 'Pulmonary arterial hypertension risk', 'Not active against T315I gatekeeper mutation'],
    source: 'FDA label; DASISION (NCT00481247); BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Scemblix',
    generic_name: 'asciminib',
    company: 'Novartis',
    indication: 'Chronic Myeloid Leukemia',
    indication_specifics: 'CP-CML previously treated with 2+ prior TKIs; also Ph+ CML with T315I mutation',
    mechanism: 'STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor—allosteric BCR-ABL1 inhibitor',
    mechanism_category: 'bcr_abl_inhibitor',
    molecular_target: 'BCR-ABL1 (myristoyl pocket)',
    phase: 'Approved',
    primary_endpoint: 'MMR',
    key_data: 'ASCEMBL: MMR 25.5% vs 13.2% bosutinib at 24 wk (p=0.029); active against T315I at 200mg BID dose',
    line_of_therapy: '3L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First-in-class allosteric mechanism—different binding site than all TKIs', 'Active against T315I mutation (at 200mg BID dose)', 'Superior to bosutinib in ASCEMBL; favorable tolerability'],
    weaknesses: ['Currently approved only in 3L+ (ASC4FIRST 1L data pending full approval)', 'Twice-daily dosing for T315I', 'Thrombocytopenia and neutropenia common'],
    source: 'FDA label; ASCEMBL (NCT03106779); Novartis 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 22. GASTRIC CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Enhertu',
    generic_name: 'fam-trastuzumab deruxtecan-nxki',
    company: 'Daiichi Sankyo/AstraZeneca',
    indication: 'Gastric Cancer',
    indication_specifics: 'Locally advanced or metastatic HER2-positive gastric/GEJ adenocarcinoma after prior trastuzumab-based regimen',
    mechanism: 'Anti-HER2 antibody-drug conjugate (topoisomerase I inhibitor DXd payload, DAR ~8)',
    mechanism_category: 'antibody_drug_conjugate',
    molecular_target: 'HER2 (ERBB2)',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'DESTINY-Gastric01: ORR 51.3% vs 14.3% chemo; OS 12.5 vs 8.4 mo (HR 0.59, p=0.01); practice-changing in 2L HER2+ GC',
    line_of_therapy: '2L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['High ORR (>50%) in 2L+ HER2+ gastric cancer', 'Significant OS benefit over chemotherapy', 'Bystander effect from membrane-permeable DXd payload'],
    weaknesses: ['ILD/pneumonitis risk (~10%, grade 5 in ~1%)', 'HER2+ only (~15-20% of gastric cancers)', 'Hematologic toxicity (neutropenia, anemia)'],
    source: 'FDA label; DESTINY-Gastric01 (NCT03329690); Daiichi/AZ 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Opdivo + chemo',
    generic_name: 'nivolumab + fluoropyrimidine/oxaliplatin',
    company: 'Bristol-Myers Squibb',
    indication: 'Gastric Cancer',
    indication_specifics: '1L advanced/metastatic gastric, GEJ, or esophageal adenocarcinoma with PD-L1 CPS ≥5',
    mechanism: 'Anti-PD-1 checkpoint inhibitor + cytotoxic chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate 649: OS 14.4 vs 11.1 mo in CPS≥5 (HR 0.71, p<0.001); PFS 7.7 vs 6.0 mo; new 1L standard',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Significant OS improvement in CPS≥5 population', 'Established as 1L standard in PD-L1+ gastric cancer', 'Active in both gastric and GEJ adenocarcinoma'],
    weaknesses: ['PD-L1 CPS≥5 required—excludes ~40% of patients', 'Immune-mediated AEs added to chemo toxicity', 'Modest absolute benefit in CPS 1-4 subgroup'],
    source: 'FDA label; CheckMate 649 (NCT02872116); BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vyloy',
    generic_name: 'zolbetuximab',
    company: 'Astellas Pharma',
    indication: 'Gastric Cancer',
    indication_specifics: '1L HER2-negative, CLDN18.2-positive, locally advanced or metastatic gastric/GEJ adenocarcinoma',
    mechanism: 'Anti-Claudin 18.2 monoclonal antibody (ADCC/CDC against CLDN18.2+ tumor cells)',
    mechanism_category: 'monoclonal_antibody',
    molecular_target: 'Claudin 18.2 (CLDN18.2)',
    phase: 'Phase 3',
    primary_endpoint: 'PFS',
    key_data: 'SPOTLIGHT: PFS 10.6 vs 8.7 mo (HR 0.75, p=0.007); OS 18.2 vs 15.5 mo (HR 0.75, p=0.02); GLOW confirmed PFS/OS benefit',
    line_of_therapy: '1L',
    partner: 'Astellas (licensed from Ganymed/Astellas)',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First-in-class Claudin 18.2 targeting—novel mechanism', 'Positive PFS and OS in two Phase 3 trials (SPOTLIGHT, GLOW)', 'CLDN18.2 expressed in ~38% of gastric cancers'],
    weaknesses: ['Nausea and vomiting common (~75%); requires anti-emetics', 'IHC 2+/3+ in ≥75% of cells—narrow biomarker cutoff', 'FDA filing pending—not yet approved'],
    source: 'Astellas; SPOTLIGHT (NCT03504397); GLOW (NCT03653507); ASCO 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 23. BASAL CELL CARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Erivedge',
    generic_name: 'vismodegib',
    company: 'Roche/Genentech',
    indication: 'Basal Cell Carcinoma',
    indication_specifics: 'Locally advanced BCC not amenable to surgery/radiation, or metastatic BCC',
    mechanism: 'Hedgehog pathway inhibitor (SMO antagonist)',
    mechanism_category: 'hedgehog_inhibitor',
    molecular_target: 'Smoothened (SMO)',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'ERIVANCE: ORR 48.5% laBCC, 33.3% mBCC; median DOR 26.2 mo laBCC; first targeted therapy for advanced BCC',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First Hedgehog inhibitor approved—established standard', 'Meaningful responses in surgically ineligible BCC', 'Oral once-daily dosing'],
    weaknesses: ['Muscle spasms (~71%), dysgeusia (~55%), alopecia (~63%)', 'High discontinuation rate (~30%) due to AEs', 'Acquired resistance through SMO mutations'],
    source: 'FDA label; ERIVANCE (NCT00833417); Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Odomzo',
    generic_name: 'sonidegib',
    company: 'Sun Pharma',
    indication: 'Basal Cell Carcinoma',
    indication_specifics: 'Locally advanced BCC that has recurred following surgery/radiation, or not candidates for surgery/radiation',
    mechanism: 'Hedgehog pathway inhibitor (SMO antagonist)',
    mechanism_category: 'hedgehog_inhibitor',
    molecular_target: 'Smoothened (SMO)',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'BOLT: ORR 56.1% at 200mg in laBCC; median DOR 26.1 mo; 42-mo follow-up confirms durable responses',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Higher ORR than vismodegib in cross-trial comparison', 'Durable responses with long-term follow-up', 'May have different resistance profile than vismodegib'],
    weaknesses: ['Similar class AE profile: muscle spasms, dysgeusia, alopecia', 'CK elevation requiring monitoring (rhabdomyolysis risk)', 'Smaller market share than first-mover Erivedge'],
    source: 'FDA label; BOLT (NCT01327053); Sun Pharma 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Libtayo',
    generic_name: 'cemiplimab-rwlc',
    company: 'Regeneron/Sanofi',
    indication: 'Basal Cell Carcinoma',
    indication_specifics: 'Locally advanced or metastatic BCC after HHI therapy or for whom HHI is not appropriate',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'Study 1620: ORR 31% in laBCC, 21% in mBCC after HHI; median DOR not reached; first IO for BCC post-HHI',
    line_of_therapy: '2L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First and only IO approved in advanced BCC', 'Addresses post-HHI unmet need', 'Durable responses (median DOR not reached)'],
    weaknesses: ['Moderate ORR (~21-31%)—not all patients respond', 'Immune-mediated AEs (colitis, hepatitis, pneumonitis)', 'Limited to HHI-pretreated or HHI-inappropriate patients'],
    source: 'FDA label; Study 1620 (NCT03132636); Regeneron 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // 24. CUTANEOUS SQUAMOUS CELL CARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Libtayo',
    generic_name: 'cemiplimab-rwlc',
    company: 'Regeneron/Sanofi',
    indication: 'Cutaneous Squamous Cell Carcinoma',
    indication_specifics: 'Metastatic or locally advanced cSCC not candidates for curative surgery or radiation',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'EMPOWER-CSCC-1: ORR 46.1% (CR 20.2%), median DOR not reached; first systemic therapy approved for advanced cSCC',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First and only FDA-approved systemic therapy for advanced cSCC', 'High ORR with durable complete responses', 'NCCN Category 1 preferred recommendation'],
    weaknesses: ['Immune-mediated AEs (~15% grade 3+)', 'Contraindicated in solid organ transplant recipients', 'Some patients with heavy prior treatment/immunosuppression do not respond'],
    source: 'FDA label; EMPOWER-CSCC-1 (NCT02760498); Regeneron 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Cutaneous Squamous Cell Carcinoma',
    indication_specifics: 'Recurrent or metastatic cSCC not curable by surgery or radiation',
    mechanism: 'Anti-PD-1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 2',
    primary_endpoint: 'ORR',
    key_data: 'KEYNOTE-629: ORR 34.3% (CR 4.3%), median DOR not reached; KEYNOTE-630 (adjuvant cSCC): negative for EFS endpoint',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Second PD-1 option for advanced cSCC', 'Keytruda brand familiarity and physician comfort', 'NCCN listed as alternative to cemiplimab'],
    weaknesses: ['Lower ORR than cemiplimab in cross-trial comparison (34% vs 46%)', 'Adjuvant trial KEYNOTE-630 failed primary endpoint', 'Not FDA-approved specifically for cSCC'],
    source: 'KEYNOTE-629 (NCT03284424); NCCN cSCC v1.2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cosibelimab',
    generic_name: 'cosibelimab',
    company: 'Checkpoint Therapeutics',
    indication: 'Cutaneous Squamous Cell Carcinoma',
    indication_specifics: 'Metastatic or locally advanced cSCC not candidates for curative surgery or radiation',
    mechanism: 'Anti-PD-L1 checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Phase 3',
    primary_endpoint: 'ORR',
    key_data: 'Phase 3 CK-301-101: ORR 47.4% (CR 14.5%); median DOR not reached; BLA submitted to FDA',
    line_of_therapy: '1L',
    nct_ids: ['NCT03212404'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['ORR comparable to cemiplimab (~47%)', 'PD-L1 target may have different AE profile than PD-1', 'BLA under FDA review—potential near-term approval'],
    weaknesses: ['Single-arm study without randomized comparator', 'Checkpoint Therapeutics small company with limited commercial infrastructure', 'Crowded IO space in cSCC with cemiplimab established'],
    source: 'Checkpoint Therapeutics; CK-301-101 (NCT03212404); ASCO 2023',
    last_updated: '2025-01-15',
  },
];
